Patents by Inventor Gillian Payne

Gillian Payne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF
    Publication number: 20240132585
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: September 8, 2023
    Publication date: April 25, 2024
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel TAVARES, Lingyun RUI, Gillian PAYNE, Viktor S. GOLDMAKER
  • METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS
    Publication number: 20230364252
    Abstract: The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (“ADC”) that reduce potency variability between batches of ADC and provide for administration of such therapeutic compositions within a narrow intended range.
    Type: Application
    Filed: December 23, 2022
    Publication date: November 16, 2023
    Inventors: Gillian PAYNE, Robert W. HERBST, Juma BRIDGEWATER
  • METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY
    Publication number: 20220143208
    Abstract: Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided.
    Type: Application
    Filed: August 31, 2021
    Publication date: May 12, 2022
    Applicant: ImmunoGen, Inc.
    Inventors: Christina N. CARRIGAN, Kathleen R. WHITEMAN, Gillian PAYNE, Sharron LADD
  • Methods for increasing efficacy of FOLR1 cancer therapy
    Patent number: 11135305
    Abstract: Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: October 5, 2021
    Assignee: ImmunoGen, Inc.
    Inventors: Christina N. Carrigan, Kathleen R. Whiteman, Gillian Payne, Sharron Ladd
  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20210032327
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: July 21, 2020
    Publication date: February 4, 2021
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 10752683
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: August 25, 2020
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Methods for formulating antibody drug conjugate compositions
    Patent number: 10603388
    Abstract: The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (“ADC”) that reduce potency variability between batches of ADC and provide for administration of such therapeutic compositions within a narrow intended range.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: March 31, 2020
    Assignee: ImmunoGen, Inc.
    Inventors: Gillian Payne, Robert W. Herbst, Juma Bridgewater
  • METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS
    Publication number: 20190365917
    Abstract: The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (“ADC”) that reduce potency variability between batches of ADC and provide for administration of such therapeutic compositions within a narrow intended range.
    Type: Application
    Filed: May 9, 2019
    Publication date: December 5, 2019
    Applicant: ImmunoGen, Inc.
    Inventors: Gillian Payne, Robert W. Herbst, Juma Bridgewater
  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20190345248
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: April 15, 2019
    Publication date: November 14, 2019
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel TAVARES, Lingyun RUI, Gillian PAYNE, Viktor S. GOLDMAKHER
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 10301385
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: May 28, 2019
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Methods for Increasing Efficacy of FOLR1 Cancer Therapy
    Publication number: 20180200383
    Abstract: Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided.
    Type: Application
    Filed: November 9, 2017
    Publication date: July 19, 2018
    Applicant: ImmunoGen, Inc.
    Inventors: Christina N. Carrigan, Kathleen R. Whiteman, Gillian Payne, Sharron Ladd
  • CA6 Antigen-Specific Cytotoxic Conjugate and Methods of Using the Same
    Publication number: 20180127511
    Abstract: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.
    Type: Application
    Filed: October 16, 1918
    Publication date: May 10, 2018
    Inventors: Gillian PAYNE, Philip CHUN, Daniel J. TAVARES
  • METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS
    Publication number: 20170348428
    Abstract: The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (“ADC”) that reduce potency variability between batches of ADC and provide for administration of such therapeutic compositions within a narrow intended range.
    Type: Application
    Filed: August 16, 2017
    Publication date: December 7, 2017
    Applicant: ImmunoGen, Inc.
    Inventors: Gillian PAYNE, Robert W. HERBST, Juma BRIDGEWATER
  • CA6 antigen-specific cytotoxic conjugate and methods of using the same
    Patent number: 9822183
    Abstract: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: November 21, 2017
    Assignee: SANOFI
    Inventors: Gillian Payne, Philip Chun, Daniel J. Tavares
  • Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
    Publication number: 20170327575
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: May 1, 2017
    Publication date: November 16, 2017
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel TAVARES, Lingyun RUI, Gillian PAYNE, Viktor S. GOLDMAKHER
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 9670280
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 6, 2017
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 9670278
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: June 6, 2017
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 9670279
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: June 6, 2017
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 9657100
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: May 23, 2017
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 9598490
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: March 21, 2017
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher